Organic Active Ingredients TRIZ Cases

Tazemetostat targets aberrant EZH2 activity to treat INI1-negative tumors, reducing morbidity while improving treatment efficacy.

Steam sterilizing an acidic chitosan and glycerol mixture prevents aggregate formation, maintaining clarity and viscosity at neutral pH.

A brivaracetam composition uses swelling excipients to expand within the stomach, maintaining gastric retention for sustained drug delivery.

A beaded nonwoven membrane reduces linear shrinkage through polymeric nanofibers.

A divalent antibody featuring a modified hinge region binds specifically to the human c-Met receptor.

Topical ophthalmic formulation with antioxidants and osmoprotectants replaces invasive surgery to prevent cataracts.

Covalent linkage of clorgyline to MHI-148 enables selective MAO A inhibition, overcoming blood-brain barrier obstruction and reversing temozolomide resistance.

Single-stranded oligonucleotides target PRC2-associated regions to enhance SMN gene expression, addressing decreased SMN activity in ALS.

A pectin-adriamycin conjugate modified with a polyethylene glycol linker enhances water solubility and tumor accumulation.

Algae-derived chondroitin sulfate protects oral mucous membranes, resolving ethical and safety concerns of animal-based treatments.

Targeting Type I taste receptors with specific ligands controls voltage-gated sodium channels to reduce neuronal hyperactivity without indiscriminate blockade.

Removes benzalkonium chloride to prevent paradoxic bronchoconstriction while maintaining stability via sterile filtration and unit-dose packaging.

Modifying endogenous RNA sequences enables canonical processing and RISC engagement, bypassing complex transgenic tools.

Polyvinyl alcohol coating isolates esomeprazole from sodium bicarbonate in multi-layered tablets to maintain chemical purity.

Modified RNAi agents inhibit INHBE expression to treat metabolic syndrome while minimizing off-target effects.

A polynucleotide composition encoding interferon-stimulated genes modulates the host immune response to inhibit viral replication.

Segmented tablet cores with modified-release coatings control dissolution rates to prevent adverse events in pediatric patients.

Sphingosine kinase type I inhibitors and receptor agonists modulate S1P signaling to treat coronavirus infections.

Ester prodrugs of urolithins resolve formulation challenges by enhancing water solubility and enabling oral absorption via in vivo hydrolysis.

Macrocyclic aminopyrazolopyrimidine compounds selectively inhibit highly activated Trk fusion proteins, overcoming the limitations of current kinase inhibitors.

A biocompatible polymer coating applied to the epicardium prevents tissue fibrosis and adhesion formation during cardiac procedures.

A carbodiimide coupling method attaches polyethylene glycol to active agents using a hydrolyzable spacer and DPTS catalyst.

Dispersed enteric-coated beads replace unstable buffering agents, extending shelf-life while maintaining palatability.

2-Indolone derivatives inhibit tyrosine kinase to block tumor growth while sparing normal cells from toxicity.

FKBP13-based domains enable dose-dependent regulation of gene-editing payloads within adeno-associated virus vectors.

Pyrrolopyrimidine derivatives achieve selective JAK1 inhibition, resolving the trade-off between immunosuppressive efficacy and adverse side effects.

Vaginal progesterone delivery replaces surgical cerclage, reducing adverse health effects while preventing preterm birth and improving neonatal outcomes.

Triazinone derivatives modulate NLRP3 activity to address the lack of effective inhibitors for autoimmune conditions.

Pyrazole 3,5-carboxylate derivatives inhibit beta-secretase BACE1 to reduce beta-amyloid peptide formation in neurodegenerative disease treatment.

A pharmaceutical composition containing MECP2 inhibitors restores damaged cognitive functions through targeted gene expression modulation.

Specific DPP-IV inhibitor compounds prolong active GLP-1 levels to improve glucose tolerance.

Quinazoline derivatives with zinc-binding moieties overcome drug-resistant tumors by adapting to mutated kinase binding pockets.

Targets immune evasion by inhibiting PD-1, TGF-beta, and MCT4 to prevent compensatory upregulation.

SKA-111 and SKA-121 activate KCa3.1 channels via modified benzoxazole scaffolds, lowering blood pressure without sedation.

Formula I compounds with modified substituents overcome evolutionary resistance to existing anthelmintic agents.

Citric acid treatment removes carcinogens from areca nuts while mucor fermentation preserves beneficial compounds for oral health.

JAK inhibitors suppress interferon kappa to boost skin cell transfection, overcoming cellular resistance.

Combining low-dose RAD001 and BEZ235 upregulates interferon-induced genes to boost antibody titers.

A dual SGLT1 and SGLT2 inhibitor reduces plasma glucose levels through combined transporter blockade.

Aminated ZnFe2O4 hollow porous magnetic nanoparticles deliver ligustrazine hydrochloride to degenerated discs via double targeting.

Aryl-substituted nitrogen-containing heterocyclic compounds inhibit nociceptin binding to the ORL1 receptor.

Combining tinostamustine with anti-CD38 antibodies increases CD38 surface expression on cancer cells to improve therapeutic efficacy.